Heart Test Labs Files 8-K on Shareholder Vote & Exhibits
Ticker: HSCSW · Form: 8-K · Filed: Feb 15, 2024 · CIK: 1468492
| Field | Detail |
|---|---|
| Company | Heart Test Laboratories, Inc. (HSCSW) |
| Form Type | 8-K |
| Filed Date | Feb 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K filing, corporate governance, regulatory filing
TL;DR
**Heart Test Labs filed an 8-K about a shareholder vote and financial exhibits, but specific details are not provided.**
AI Summary
Heart Test Laboratories, Inc. filed an 8-K on February 15, 2024, reporting the submission of matters to a vote of security holders and the filing of financial statements and exhibits. The filing, dated February 15, 2024, did not disclose specific details regarding the nature of the vote or the contents of the financial statements.
Why It Matters
This 8-K indicates that Heart Test Laboratories, Inc. has taken actions requiring shareholder approval or has filed important financial documents, signaling ongoing corporate activity that could impact investors.
Risk Assessment
Risk Level: low — The 8-K is a standard regulatory filing announcing a vote and exhibit submission, without disclosing specific events that would inherently carry high risk.
Key Players & Entities
- Heart Test Laboratories, Inc. (company) — registrant
- February 15, 2024 (date) — date of report
- Texas (state) — state of incorporation
- Southlake (city) — business address
- 682-237-7781 (phone_number) — registrant's telephone number
FAQ
What is the full legal name of the registrant?
The exact name of the registrant as specified in its charter is Heart Test Laboratories, Inc.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is February 15, 2024.
What specific items were reported in this 8-K filing?
The items reported were "Submission of Matters to a Vote of Security Holders" and "Financial Statements and Exhibits."
In which state is Heart Test Laboratories, Inc. incorporated?
Heart Test Laboratories, Inc. is incorporated in Texas.
What is the business address of the registrant?
The business address is 550 Reserve Street, Suite 360, Southlake, Texas, 76092.
Filing Stats: 624 words · 2 min read · ~2 pages · Grade level 13.4 · Accepted 2024-02-15 16:30:02
Filing Documents
- hscs-20240215.htm (8-K) — 55KB
- 0000950170-24-015929.txt ( ) — 204KB
- hscs-20240215.xsd (EX-101.SCH) — 48KB
- hscs-20240215_htm.xml (XML) — 6KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. As previously reported, on January 17, 2024, Heart Test Laboratories, Inc. (the "Company") convened its 2024 Annual Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the Company's shareholders voted on eight proposals which are described in detail in the Company's definitive proxy statement for its 2024 Annual Meeting of Shareholders filed with the U.S. Securities and Exchange Commission (the "SEC") on December 8, 2023 (the "Proxy Statement"). As also previously reported, with respect to Proposal 7, the Company did not receive sufficient proxies from shareholders to approve an amendment to the Company's Certificate of Formation to decrease the number of shares of the Company's Common Stock needed to establish a quorum for meetings of the Company's shareholders. Accordingly, the Company adjourned the Annual Meeting with respect to Proposal 7 in order to continue to solicit votes from its shareholders. On February 15, 2024, the Company held its reconvened Annual Meeting in order to vote on Proposal 7. The results for the proposal submitted to a vote of shareholders at the reconvened Annual Meeting are as follows: Proposal 7: Quorum Reduction Proposal The Company's shareholders approved an amendment to the Company's Certificate of Formation to decrease the number of shares of the Company's Common Stock needed to establish a quorum for meetings of the Company's shareholders by voting as follows: For Against Abstain Broker Non-Votes 27,172,440 1,298,890 362,117 1,015,919
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HEART TEST LABORATORIES, INC. Date: February 15, 2024 By: /s/ Andrew Simpson Name: Title: Andrew Simpson President, Chief Executive Officer, and Chairman of the Board of Directors